Picture Kentro Design Corporate and Web Design for Start Ups 2x 650x80px
Organisation › Details

Ionis Pharmaceuticals (Group)

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in the U.S., Europe, Japan and Canada for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen (IONIS-TTRRx), an antisense drug Ionis is developing to treat patients with TTR amyloidosis, and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Both inotersen and volanesorsen are progressing toward regulatory filings for marketing authorization. Ionis' patents provide strong and extensive protection for its drugs and technology. *


Period Start 2015-12-01 renamed
  Predecessor Isis Pharmaceuticals (Group)
Products Industry pharmaceutical
  Industry 2 antisense drug
Persons Person Crooke, Stanley T. (Isis Pharmaceuticals 200604 CEO)
  Person 2 Parshall, B. Lynne (Isis Pharmaceuticals 200604 CFO)
Region Region Carlsbad, CA
  Country United States (USA)
  Street 2855 Gazelle Court
  City 92010 Carlsbad, CA
  Tel +1-760-931-9200
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Ionis Pharmaceuticals, Inc.. (8/11/17). "Press Release: Ionis to Independently Advance Inotersen and Ionis-FB-L Rx". Carlsbad, CA.
Record changed: 2021-12-30


Picture [iito] Fighting Customers 650x100px

More documents for Ionis Pharmaceuticals (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] [LSE] Business Portal 650x300px

» top